Instalab

Cystatin C Test: Is It a Smarter Measure of Kidney Function Than Creatinine?

When we think about kidney health, most of us have heard of “creatinine” levels as the go-to test. But in recent years, doctors have been paying more attention to another blood test: the cystatin C test. Unlike creatinine, cystatin C is less affected by factors like age, sex, or muscle mass, which makes it a promising alternative for measuring kidney function. Even more interesting, studies suggest that cystatin C may also be an early warning sign for heart disease and overall mortality.
Instalab Research

What is Cystatin C?

Cystatin C is a small protein produced by nearly every cell in the body. Its main job is to help regulate enzymes that break down proteins. But what makes cystatin C clinically important is how it moves through the kidneys. It is filtered out of the blood by the kidneys’ tiny filters (the glomeruli) and then broken down completely by the kidney tubules. That means blood levels of cystatin C directly reflect how well the kidneys are filtering.

Unlike creatinine, which can be influenced by muscle size, diet, or age, cystatin C levels tend to stay more consistent across people. This gives it an advantage in detecting small changes in kidney function that might otherwise be missed.

Cystatin C vs. Creatinine: Which is Better?

Creatinine has been the standard marker for decades, but it has its drawbacks. Since creatinine is a byproduct of muscle metabolism, athletes or people with larger muscle mass may appear to have worse kidney function than they actually do. On the other hand, elderly individuals or those with very little muscle mass may appear healthier than they are.

Cystatin C largely avoids these pitfalls. Research has shown that cystatin C can detect mild reductions in kidney function that creatinine often misses. In elderly populations, higher cystatin C levels were linked to increased risks of death, stroke, and heart disease, even when creatinine-based tests suggested kidney function was normal.

Cystatin C as an Early Warning for Heart Disease

Here’s where things get even more interesting: cystatin C does not just tell us about kidney health. A growing body of research shows that higher cystatin C levels are linked to future cardiovascular events such as heart attacks, heart failure, and strokes. In fact, several large studies found that cystatin C predicts heart problems and death even in people without diagnosed kidney disease.

For example, in the AtheroGene study of over 1,800 patients with coronary artery disease but normal kidney function, those with the highest cystatin C levels were nearly four times more likely to die from cardiovascular causes compared to those with lower levels. Importantly, creatinine did not show the same predictive power in this group.

Another long-term study, the LIPID trial, followed more than 7,800 people with a history of heart disease for up to 16 years. It found that higher cystatin C levels predicted major cardiovascular events and death, even after accounting for traditional risk factors and better estimates of kidney function.

Why Might Cystatin C Predict Heart Problems?

The link between cystatin C and cardiovascular disease is not fully understood, but researchers have some theories. One explanation is that cystatin C is simply a more sensitive measure of kidney function. Since even mild kidney problems are strongly tied to cardiovascular risk, cystatin C may just be revealing that hidden connection earlier than creatinine.

But there may also be more direct roles. Cystatin C interacts with enzymes involved in inflammation and blood vessel remodeling. Some studies suggest that low local levels of cystatin C in artery walls might contribute to plaque buildup and aneurysm formation. So cystatin C could be doing double duty as both a marker of kidney function and a player in heart health.

Cystatin C in Special Populations

Cystatin C has shown particular value in groups where creatinine is less reliable. For instance, in people living with HIV, cystatin C revealed worse kidney function than creatinine suggested. Those with higher cystatin C levels also had more risk factors for heart disease, such as high blood pressure and low HDL cholesterol.

In children, where growth and muscle changes make creatinine especially tricky, cystatin C appears to be more accurate for detecting early kidney problems. This includes conditions like congenital malformations of the urinary tract and acute kidney injury in intensive care settings.

Should the Cystatin C Test Be Used Routinely?

Given the strong evidence, should doctors start ordering cystatin C tests for everyone? Some experts argue that it could transform how we detect early kidney disease and prevent heart complications. In fact, international kidney disease guidelines now recommend equations that combine both creatinine and cystatin C for the most accurate estimate of kidney function.

However, there are challenges. Cystatin C testing is more expensive than creatinine and not yet available in every lab. There is also ongoing research into whether factors like inflammation may sometimes affect cystatin C levels independently of kidney function.

Cystatin C’s Growing Role in Medicine

The cystatin C test is proving to be much more than just an alternative to creatinine. It offers a clearer picture of kidney function, especially in its early decline, and serves as a powerful predictor of heart disease and death. While cost and availability remain hurdles, the science is pointing toward cystatin C becoming a standard part of medical practice in the near future.

References
  • Bökenkamp, A., Herget-Rosenthal, S., & Bökenkamp, R. (2006). Cystatin C, kidney function and cardiovascular disease. Pediatric Nephrology, 21, 1223-1230. https://doi.org/10.1007/s00467-006-0192-5.
  • Wagner, C. (2008). Cystatin C, Renal Function and Cardiovascular Risk. , 27, 426 - 431. https://doi.org/10.2478/v10011-008-0021-4.
  • Shlipak, M., Katz, R., Sarnak, M., Fried, L., Newman, A., Stehman-Breen, C., Seliger, S., Kestenbaum, B., Psaty, B., Tracy, R., & Siscovick, D. (2006). Cystatin C and Prognosis for Cardiovascular and Kidney Outcomes in Elderly Persons without Chronic Kidney Disease. Annals of Internal Medicine, 145, 237-246. https://doi.org/10.7326/0003-4819-145-4-200608150-00003.
  • Keller, T., Messow, C., Lubos, E., Nicaud, V., Wild, P., Rupprecht, H., Bickel, C., Tzikas, S., Peetz, D., Lackner, K., Tiret, L., Münzel, T., Blankenberg, S., & Schnabel, R. (2009). Cystatin C and cardiovascular mortality in patients with coronary artery disease and normal or mildly reduced kidney function: results from the AtheroGene study.. European heart journal, 30 3, 314-20 . https://doi.org/10.1093/eurheartj/ehn598.
  • West, M., Kirby, A., Stewart, R., Blankenberg, S., Sullivan, D., White, H., Hunt, D., Marschner, I., Janus, E., Kritharides, L., Watts, G., Simes, J., & Tonkin, A. (2022). Circulating Cystatin C Is an Independent Risk Marker for Cardiovascular Outcomes, Development of Renal Impairment, and Long‐Term Mortality in Patients With Stable Coronary Heart Disease: The LIPID Study. Journal of the American Heart Association: Cardiovascular and Cerebrovascular Disease, 11. https://doi.org/10.1161/JAHA.121.020745.
  • Odden, M., Scherzer, R., Bacchetti, P., Szczech, L., Sidney, S., Grunfeld, C., & Shlipak, M. (2007). Cystatin C level as a marker of kidney function in human immunodeficiency virus infection: the FRAM study.. Archives of internal medicine, 167 20, 2213-9 . https://doi.org/10.1001/ARCHINTE.167.20.2213.
  • Skidmore, M., Spencer, S., Desborough, R., Kent, D., & Bhandari, S. (2024). Cystatin C as a Marker of Kidney Function in Children. Biomolecules, 14. https://doi.org/10.3390/biom14080938.
  • Bevc, S., Ekart, R., & Hojs, R. (2021). Cystatin c – a marker of kidney function and predictor of cardiovascular disease and mortality. Acta Medico-Biotechnica. https://doi.org/10.18690/actabiomed.95.
  • Shlipak, M., Praught, M., & Sarnak, M. (2006). Update on cystatin C: new insights into the importance of mild kidney dysfunction. Current Opinion in Nephrology and Hypertension, 15, 270–275. https://doi.org/10.1097/01.mnh.0000222694.07336.92.